Keyword: Soliris

After halting phase 3 trials for its APL-2 drug in geographic atrophy on safety concerns, Apellis says it will restart the program next year.

Chugai has the phase 3 data it needs to file IL-6-targeting antibody satralizumab for approval in neuromyelitis optica spectrum disorder next year.

A phase 2 win for its lead drug in myasthenia gravis has Ra Pharma pressing the button on a $115 million public funding round.

The deal will see Alexion work with Complement to take a C6 complement inhibitor through phase 1b and decide whether to execute a takeover.

The success positions Alexion to file for approval and shield itself from an anticipated assault on its paroxysmal nocturnal hemoglobinuria franchise.

Alexion hit key endpoints for its experimental phase 3 drug ALXN1210 in patients with a life-threatening ultrarare blood disorder.

Alexion is slashing its workforce by around 20% and closing sites in a bid to save $250 million a year, with R&D bearing the brunt.

Apellis reported positive midstage data for its lead candidate in age-related macular degeneration shortly after a $60 million series E raise.

Omeros has defended the data supporting its mooted rival to Soliris after STAT sought answers to questions raised by a short seller.

The CEO of Akari Therapeutics has quit amid a probe into the release of phase 2 data and a related analyst report.